Brilliant speaker line-up for this event in Berlin just before ESMO on the 16th October 2025 at the Westin Grand.. For more details see www.worldcupalliance.org
Alison Taylor, acute oncology and CUP nurse consultant at The Clatterbridge Cancer Centre has just returned for a 5 week trip to Australia as part of her Churchill fellowship. This work focuses on improving support for people with cancer of unknown primary (CUP). She will also link in with teams in the Netherlands and the USA in 2025. The inspiration
Read more
ESMO have included CUP in their programme and the speakers are our well known CUP researchers: Linda Mileshkin, Alwin Kramer, Natalie Cook, Harpreet Wasan, and Manel Esteller. For the CUP events go to the programme and look at the Toledo venue starting Saturday 14 Sep.
The American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago in June 2024. Although there was limited CUP research presented we wanted to highlight two studies presented as posters at this meeting: The UK CUPCOMP study was presented by Dr Alicia-Marie Conway, University of Manchester, Cancer Research UK National Biomarker Centre and The Christie NHS TRust (photo
Read more
Very comprehensible article on how examining circulating tumour DNA from liquid biopsies will change the search for CUP based on the proof of concept research by Dr Conway at The Christie. A new blood test for cancer of unknown primary (cancerresearchuk.org)
A new initiative from Natalie Cook and the CUP team at The Christie giving patient-friendly update on research and patient group meetings TheCatchUP_1stEdition_November2023
Dr Natalie Cook has been awarded a 5-year National Institute for Health and Care Research (NIHR) Rosetrees Trust Advanced Fellowship. The £730,000 award will fund an ambitious and exciting programme of research into cancer of unknown primary (CUP). https://www.christie.nhs.uk/research-and-innovation/research-newsroom/research-news/christie-consultant-awarded-5-year-advanced-clinical-fellowship
The abstract presented at ESMO by Dr Harpreet Wasan – PI of the CUP-One trial: A prospective double-blind validation of molecular classifiers in the diagnosis of Cancer of Unknown Primary and clinical outcome. CUP-ONE esmo abs
LBA16 – Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP) Background With platinum-based CTX, prognosis of patients (pts) with unfavourable CUP is poor; however, CGP may inform treatment strategies
Read more
Prof. Penelope Schofield, Talk Topic: Understanding Lived Experiences of People with CUP: How can clinicians help? 📅 Thursday 19th October 2023 ⏰ 08:00 – 09:00 🎟 To register please email
[email protected] 📍 MS Teams (link provided following registration).